Author/Authors :
Brian S. Brown، نويسنده , , Ryan Keddy، نويسنده , , Guo Zhu Zheng، نويسنده , , Robert G. Schmidt، نويسنده , , John R. Koenig، نويسنده , , Heath A. McDonald، نويسنده , , Bruce R. Bianchi، نويسنده , , Prisca Honore، نويسنده , , Michael F. Jarvis، نويسنده , , Carol S. Surowy، نويسنده , , James S. Polakowski، نويسنده , , Kennan C. Marsh، نويسنده , , Connie R. Faltynek، نويسنده , , Chih-Hung Lee، نويسنده ,
Abstract :
A series of 1,2,3,6-tetrahydropyridyl-4-carboxamides, exemplified by 6, have been synthesized and evaluated for in vitro TRPV1 antagonist activity, and in vivo analgesic activity in animal pain models. The tetrahydropyridine 6 is a novel TRPV1 receptor antagonist that potently inhibits receptor-mediated Ca2+ influx in vitro induced by several agonists, including capsaicin, N-arachidonoyldopamine (NADA), and low pH. This compound penetrates the CNS and shows potent anti-nociceptive effects in a broad range of animal pain models upon oral dosing due in part to its ability to antagonize both central and peripheral TRPV1 receptors. The SAR leading to the discovery of 6 is presented in this report.
Keywords :
Vanilloid , CNS , Tetrahydropyridinec , Pain , TRPV1